Literature DB >> 3304899

Correlations between fasting plasma C-peptide, glucagon-stimulated plasma C-peptide, and urinary C-peptide in insulin-treated diabetics.

H J Gjessing, L E Matzen, A Frøland, O K Faber.   

Abstract

This study correlated fasting plasma C-peptide (CP), plasma CP 6 min after stimulation with 1 mg glucagon i.v., and the mean of three 24-h urinary excretions of C-peptide (UCP)/creatinine in 132 insulin-treated diabetics. Patients were divided into three groups: group 1, stimulated CP less than 0.06 nM (n = 51); group 2, stimulated CP 0.06-0.60 nM (n = 48); and group 3, stimulated CP greater than 0.60 nM (n = 33). In all patients fasting CP was closely correlated to stimulated CP (r = .988, P less than .001), whereas the correlations between UCP and both fasting CP (r = .904, P less than .001) and stimulated CP r = .902, P less than .001) were slightly less pronounced. The associations between UCP and both fasting CP (r = .716, P less than .001) and stimulated CP (r = .731, P less than .001) were modest in group 2, and even more so in group 3 (r = .557, P less than .001 and r = .641, P less than .001, respectively). In conclusion, fasting CP is closely correlated to glucagon-stimulated CP in insulin-treated diabetics and can probably be used equally well in the assessment of beta-cell function. The associations between UCP and both fasting and glucagon-stimulated CP are less pronounced, especially in patients with well-preserved beta-cell function.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3304899     DOI: 10.2337/diacare.10.4.487

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  12 in total

1.  Islet cell antibodies and fasting C-peptide predict insulin requirement at diagnosis of diabetes mellitus.

Authors:  M Landin-Olsson; K O Nilsson; A Lernmark; G Sundkvist
Journal:  Diabetologia       Date:  1990-09       Impact factor: 10.122

2.  Fasting plasma C-peptide, glucagon stimulated plasma C-peptide, and urinary C-peptide in relation to clinical type of diabetes.

Authors:  H J Gjessing; L E Matzen; O K Faber; A Frøland
Journal:  Diabetologia       Date:  1989-05       Impact factor: 10.122

3.  Urine C-peptide creatinine ratio is a noninvasive alternative to the mixed-meal tolerance test in children and adults with type 1 diabetes.

Authors:  Rachel E J Besser; Johnny Ludvigsson; Angus G Jones; Timothy J McDonald; Beverley M Shields; Bridget A Knight; Andrew T Hattersley
Journal:  Diabetes Care       Date:  2011-02-01       Impact factor: 19.112

Review 4.  The clinical utility of C-peptide measurement in the care of patients with diabetes.

Authors:  A G Jones; A T Hattersley
Journal:  Diabet Med       Date:  2013-07       Impact factor: 4.359

5.  Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced β-cell function.

Authors:  Ryota Usui; Daisuke Yabe; Hitoshi Kuwata; Shuichi Fujiwara; Koin Watanabe; Takanori Hyo; Akihiro Yasuhara; Masahiro Iwasaki; Naomi Kitatani; Kyoko Kuwabara; Kayo Yokota; Takeshi Kurose; Yutaka Seino
Journal:  J Diabetes Investig       Date:  2013-06-25       Impact factor: 4.232

6.  Lessons from the mixed-meal tolerance test: use of 90-minute and fasting C-peptide in pediatric diabetes.

Authors:  Rachel E J Besser; Beverley M Shields; Rosaura Casas; Andrew T Hattersley; Johnny Ludvigsson
Journal:  Diabetes Care       Date:  2012-10-30       Impact factor: 19.112

7.  Fasting serum C-peptide is useful for initial classification of diabetes mellitus in children and adolescents.

Authors:  Min Jung Cho; Min Sun Kim; Chan Jong Kim; Eun Young Kim; Jong Duk Kim; Eun Young Kim; Dae-Yeol Lee
Journal:  Ann Pediatr Endocrinol Metab       Date:  2014-06-30

8.  Post-glucose-load urinary C-peptide and glucose concentration obtained during OGTT do not affect oral minimal model-based plasma indices.

Authors:  Sjaam Jainandunsing; J L Darcos Wattimena; Trinet Rietveld; Joram N I van Miert; Eric J G Sijbrands; Felix W M de Rooij
Journal:  Endocrine       Date:  2015-11-02       Impact factor: 3.633

9.  Modulation of Autoimmune T-Cell Memory by Stem Cell Educator Therapy: Phase 1/2 Clinical Trial.

Authors:  Elias Delgado; Marcos Perez-Basterrechea; Beatriz Suarez-Alvarez; Huimin Zhou; Eva Martinez Revuelta; Jose Maria Garcia-Gala; Silvia Perez; Maria Alvarez-Viejo; Edelmiro Menendez; Carlos Lopez-Larrea; Ruifeng Tang; Zhenlong Zhu; Wei Hu; Thomas Moss; Edward Guindi; Jesus Otero; Yong Zhao
Journal:  EBioMedicine       Date:  2015-11-05       Impact factor: 8.143

10.  Islet Function and Insulin Sensitivity in Latent Autoimmune Diabetes in Adults Taking Sitagliptin: A Randomized Trial.

Authors:  Lin Yang; Huiying Liang; Xinyuan Liu; Xia Wang; Ying Cheng; Yunjuan Zhao; Lingjiao Liu; Gan Huang; Xiangbing Wang; Zhiguang Zhou
Journal:  J Clin Endocrinol Metab       Date:  2021-03-25       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.